MktsMarkets

Allogene Therapeutics, Inc.
NASDAQ: ALLOKey statistics
ALLO News
Stories mentioning ALLO from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | |||||||
| Operating Expenses | ||||||||
| Research & Development | 32,003 | 28,632 | 31,164 | 40,156 | 50,200 | 44,972 | 44,713 | 50,355 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 46,092 | 42,404 | 44,901 | 56,819 | 65,191 | 60,490 | 71,774 | 71,431 |
| Operating Income (Loss) | (46,092) | (42,404) | (44,901) | (56,819) | (65,191) | (60,490) | (71,774) | (71,431) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 212.00 | 247.00 | (81.00) | (43.00) | 92.00 | (1,952) | (1,124) | 85.00 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (42,607) | (38,810) | (41,400) | (50,943) | (59,733) | (59,939) | (66,293) | (66,358) |
| Earnings Per Share (Basic) | (0.18) | (0.18) | (0.19) | (0.23) | (0.28) | (0.31) | (0.32) | (0.35) |
| Earnings Per Share (Diluted) | (0.18) | (0.18) | (0.19) | (0.23) | (0.28) | (0.31) | (0.32) | (0.35) |
| Weighted Average Shares Outstanding (Basic) | 240,291 | 220,623 | 222,039 | 218,930 | 215,359 | 194,812 | 209,189 | 190,027 |
| Weighted Average Shares Outstanding (Diluted) | 240,291 | 220,623 | 222,039 | 218,930 | 215,359 | 194,812 | 209,189 | 190,027 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ALLO
Allogene Therapeutics, Inc. (NASDAQ: ALLO) is a stock listed on the Nasdaq Stock Market under the ticker symbol ALLO. It last traded at $0.7500 (Nov 17, 2026, 2:23 PM ET), down 6.8% on the day. That gives Allogene Therapeutics a market capitalisation of $270.3M.
Over the past 52 weeks ALLO has traded between $0.8200 and $4.46.
For the quarter ended Mar 31, 2026 it reported a net loss of $42.6M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$42.6M |
| Dec 31, 2025 | $0 | -$38.8M |
| Sep 30, 2025 | $0 | -$41.4M |
| Jun 30, 2025 | $0 | -$50.9M |
From Allogene Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…